

References:

1. **Aftab R, Barnes PF.(2004)** The influence of epidemiologic factors on drug resistance rates in tuber culosis. *Am Rev Respir Dis*.
2. **Allote E, Rajbhandary S, Marlls SM, Bock N. (2001)** Costs of patients hospitalized for multidrug-resistant tuberculosis. *Int J Tuberc Dis*. 2004;8:1012-1016.
3. **Anderson, D. H., G. Harth, M. A. Horwitz, and D. Eisenberg .(2001)** An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the *Mycobacterium tuberculosis* 30 kDa major secretory protein (antigen 85B), a mycolyl transferase. *J. Mol. Biol.* **307**:671-681.
4. **Bannon M; Finn, A. (1999).** ["BCG and tuberculosis"](#). Arch Dis Child 80 (1)
5. **Bonah C (2005).** "The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933". Stud Hist Philos Biol Biomed Sci 36
6. **Borgdorff, MW, Behr, MA, Nagelkerke, NJ, (2000).** Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. Int J Tuberc Lung Dis.
7. **Brennan P. J., Nikaido H. (1995).** The envelope of mycobacteria. Annu. Rev. Biochem. 64:29-63.

- 8. Brennan PJ, Nikaido H (1995).** "The envelope of mycobacteria". *Annu. Rev. Biochem.* 64: 29-63.
- 9. Bruke RM (1955)** An Historical Chronology of Tuberculosis, Second Edition, Charles C Thomas, Springfield, Illinois.
- 10. Centers for Disease Control and Prevention. (2004).** TB elimination: now is the time! Centers for Disease Control and Prevention, Atlanta, Ga.
- 11. Centers for Disease Control and Prevention. (2006).** TB elimination. Centers for Disease Control and Prevention, Atlanta, Ga.
- 12. Comstock, GW. (1994)** Epidemiology of tuberculosis. *Am J. Rev Respir Dis*; 125
- 13. De Voss JJ, Rutter K, Schroeder BG, Su H, Zhu Y, Barry CE (2000).** 3rd. The salicylate-derived mycobactin siderophores of *Mycobacterium tuberculosis* are essential for growth in macrophages. *Proc Natl Acad Sci USA* 2000; 97: 1252-
- 14. Draper P. (1982)** The anatomy of mycobacteria. In *The Biology of Mycobacteria*. J Ed Academic Press, London, p 9-52
- 15. Dye, C. (2005)** Global epidemiology of tuberculosis. *Lancet* 367:938.
- 16. Fine P, Floyd S, Stanford J, Nkhosa P, Kasunga A, Chaguluka S, Warndorff D, Jenkins P, Yates M, Ponnighaus J (2001).** "Environmental mycobacteria in

northern Malawi: implications for the epidemiology of tuberculosis and leprosy". *Epidemiol Infect* 126

17. **Forbes B.A; Sahm D.F; Weissfeld A.S (2007).** Diagnostic microbiology, 12th addition, mosby, UK, Ch 45, page 478.
18. **Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., & Dye, C. (2003).** Tuberculosis. *Lancet*, 362(9387), 887-99.
19. **Garton NJ, Christensen H, Minnikin DE, Adegbola RA, Barer MR.(2002)** Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. *Microbiology* 2002; 148: 2951-8.
20. **Geo. F. Brooks, J. S. B., & Stephen A. Morse. (2001).** Mycobacteria. In: Geo. F. **Brooks, J. S. B., Morse, S.A., eds. Jawetz, Melnick, & Adelberg's** Medical Microbiology. McGraw-Hill, New York, pp. 275-284.

<http://lgsbs.utmb.edu/microbook/ch033.htm>
21. **Kaufmann S. H. E. and Hess J., (2000).** Immune response against *Mycobacterium tuberculosis*: Implications for vaccine development. *J. Biotech.* 83:13-17.
22. **Kremer, L., L. G. Dover, S. Carrere, K. M. Nampoothiri, S. Lesjean, A. K. Brown, P. J. Brennan, D. E. Minnikin, C. Locht, and G. S. Besra. (2002).** Mycolic acid biosynthesis and enzymic characterization of the β -ketoacyl-ACP synthase . *Biochem. J.* 364:423-430. 53

23. **Kumar P., Calrk M.(2001);** Clinical Medicine; 6th edition; Saunders. Page 801 - 802
24. **Lowel AM, Edwar LB, Balmer CE (1969).** Tuberculosis. Vital and Health statistics Monograph, American Puplic Health Association. Harvard University Press, Cambridge.
25. **Manchester, Keith (1984)** Tuberculosis and Leprosy in Antiquity: An Interpretation. [Abstract]. *MASCA Journal* 3(3):89.
26. **Martin C (May 2006).** "Tuberculosis vaccines: past, present and future". *Curr Opin Pulm Med* 12 (3): 186-91.
27. **McMurray, D. N. (2005).** Mycobacteria and Nocardia. In: Baron, S., ed. Medical Microbiology. Churchill Livingstone, New York.
28. **Minnikin D.E., Kremer L., Dover L.G.and Besra G.S. (2002).** The Methyl-branched fortification of Mycobacterium tuberculosis. *Chem Biol* 9; 545-553.
29. **Monack D.M., Mueller A., Falkow S. (2004)** Persistent bacterial infections: the interface of the pathogen and the host immune system. *Nat. Rev. Microbiol.*;2:747-765. [*PubMed*]
30. **Morse, D., B.R. Brothweel and T.J.T. Ucko (1964).** Tuberculosis in Egypt. *Am. Reb.Dis. Resp.*, 90: 524
31. **Narain J. P., Raviglione M. A. and Kochi A. (1992).** HIV-associated tuberculosis in developing countries:

epidemiology and strategies for prevention. *Tuberc. Lung Dis.* 73:311-321.

- 32. Noordhoek GT, van Embden JD, Kolk AH. (1994).** Reliability of nucleic acid amplification for detection of *Mycobacterium tuberculosis*: an international collaborative quality control study among 30 laboratories. *J Clin Microbiol* 32: 2522-2525
- 33. O'Brien R (1994).** "Drug-resistant tuberculosis: etiology, management and prevention". *Semin Respir Infect* 9.
- 34. Palomino J. C., Leao S. C. and Ritacco V. (2007) ;** Tuberculosis 2007 From basic science to patient care. First edition. TuberculosisTextbook.com.
- 35. Pan, J., Fujiwara, N., Oka, S., Maekura, R., Ogura, T., Yano, I., (1999).** Anti-Cord Factor (Trehalose 6,6'-Dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acid subclasses. *Microbiol. Immunol.* 43(9), 863-869.
- 36. Persing D. H., Smith T. F. and Tenover F. C. (1993);** Diagnostic Molecular Microbiology; Principles and Applications; ;P.Imprenta; Washington DC, Pages 191-195
- 37. Portaels, F. (1995).** Epidemiology of mycobacterial diseases. *Clin Dermatol*, 13(3), 207-22.
- 38. Raman K, Rajagopalan P, Chandra N (2005).** Flux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs. *PLoS Computational Biology* 1(5): 349:358

- 39. Ryan Kenneth J. and Ray C. George, (2004).** Sherris Medical Microbiology, an introduction to infectious diseases. 4th Edition. McGraw-Hill Companies, Inc.
- 40. Sadoff, Jerry. (2006)** Advances in Tuberculosis Vaccine Strategies. Nature Reviews Microbiology. Vol. 4. June.
- 41. Sirakova T.D., Thirumala A.K., Dubey V.S., Sprecher H. and Kolattukudy P.E. (2001).** The Mycobacterium tuberculosis pks2 gene encode the synthase for the hepta- and octamethyl branched fatty acids required for sulpholipid synthesis. *J Boil Chem* 276
- 42. Stodola, F.H., Lesuk, A., and Anderson, R.J. (1938).** The chemistry of the lipids of Tubercle bacilli liv. The isolation and properties of mycolic acid. *J. Biol. Chem.* 126:505-513.
- 43. Takayama K, Wang C, Besra GS (2005)** Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clinical Microbiology Reviews 18: 81-101
- 44. van Soolingen D, Hoogenboezem T, de Haas PE, et al. (October 1997).** ["A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa"](#). *Int. J. Syst. Bacteriol.*
- 45. Verschoor, J. A., Lenaerts, A. & Johannsen, E., (2009).** A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the

prevention, treatment and diagnosis of disease. Patent application no. PCT/GB98/00681

- 46. Wayne LG. (1982);** Microbiology of tubercle bacilli. Am Rev Respir Dis 1982; 125: 31-41.
- 47. WHO, (1993).** WHO attacks global neglect of tuberculosis crisis. Millions dying from `low priority` disease.
- 48. WHO, (2006).** WHO attacks global neglect of tuberculosis disease.
- 49. Williams, J and Wilkins, PK (1939).** The Genuine Work of Hippocrates. Paltmore p 101-133.
- 50. Yoshimura, C. Miyagi, and S. Goto. (1993).** Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test. *J. Clin. Microbiol.* 31: 3270-3274.